Coen Hemker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7979995/publications.pdf

Version: 2024-02-01

294 papers	13,683 citations	34105 52 h-index	24982 109 g-index
299 all docs	299 docs citations	299 times ranked	6206 citing authors

#	Article	IF	Citations
1	Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet, The, 1990, 335, 1544-1547.	13.7	1,294
2	Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers.. Journal of Biological Chemistry, 1990, 265, 4923-4928.	3.4	573
3	The Calibrated Automated Thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 249-253.	0.3	566
4	The role of phospholipids and factor Va in the prothrombinase complex. Journal of Biological Chemistry, 1980, 255, 274-83.	3.4	454
5	Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers. Journal of Biological Chemistry, 1990, 265, 4923-8.	3.4	433
6	Generation of Prothrombin-Converting Activity and the Exposure of Phosphatidylserine at the Outer Surface of Platelets. FEBS Journal, 1982, 122, 429-436.	0.2	426
7	The role of phospholipid and factor VIIIa in the activation of bovine factor X. Journal of Biological Chemistry, 1981, 256, 3433-42.	3.4	393
8	The adsorption of prothrombin to phosphatidylserine multilayers quantitated by ellipsometry.. Journal of Biological Chemistry, 1983, 258, 2426-2431.	3.4	362
9	Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".. Journal of Clinical Investigation, 1996, 98, 863-874.	8.2	362
10	Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using secondâ€•and thirdâ€generation oral contraceptives. British Journal of Haematology, 1997, 97, 233-238.	2.5	324
11	Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thrombosis and Haemostasis, 2005, 93, 475-480.	3.4	295
12	Continuous Registration of Thrombin Generation in Plasma, Its Use for the Determination of the Thrombin Potential. Thrombosis and Haemostasis, 1993, 70, 617-624.	3.4	278
13	The adsorption of prothrombin to phosphatidylserine multilayers quantitated by ellipsometry. Journal of Biological Chemistry, 1983, 258, 2426-31.	3.4	256
14	Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis. Blood, 2014, 123, 1098-1101.	1.4	242
15	A Computer Assisted Method to Obtain the Prothrombin Activation Velocity in Whole Plasma Independent of Thrombin Decay Processes. Thrombosis and Haemostasis, 1986, 56, 009-017.	3.4	218
16	Peptide Bond Cleavages and Loss of Functional Activity during Inactivation of Factor Va and Factor VaR506Q by Activated Protein C. Journal of Biological Chemistry, 1995, 270, 21158-21166.	3.4	215
17	Effects of Protein S and Factor Xa on Peptide Bond Cleavages during Inactivation of Factor Va and Factor VaR506Q by Activated Protein C. Journal of Biological Chemistry, 1995, 270, 27852-27858.	3.4	207
18	Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. FEBS Journal, 1985, 151, 625-629.	0.2	164

#	Article	IF	Citations
19	Clustering of lipid-bound annexin V may explain its anticoagulant effect. Journal of Biological Chemistry, 1992, 267, 17907-12.	3.4	161
20	Thrombin generation: What have we learned?. Blood Reviews, 2012, 26, 197-203.	5.7	144
21	Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. Journal of Thrombosis and Haemostasis, 2004, 2, 476-484.	3.8	128
22	Nature of Prothrombin Biosynthesis : PreprothrombinÃ¦mia in Vitamin K-deficiency. Nature, 1963, 200, 589-590.	27.8	121
23	A Doubleâ€blind Trial of Longâ€term Anticoagulant Treatment after Myocardial Infarction. Acta Medica Scandinavica, 1967, 182, 549-566.	0.0	118
24	Factor Va-factor Xa interaction. Effects of phospholipid vesicles of varying composition. Biochemistry, 1982, 21, 5494-5502.	2.5	112
25	Ellipsometry as a tool to study protein films at liquid-solid interfaces. Analytical Biochemistry, 1978, 84, 56-67.	2.4	102
26	Thrombin generation assays: accruing clinical relevance. Current Opinion in Hematology, 2004, 11, 170-175.	2.5	101
27	Whole-Blood Thrombin Generation Monitored with a Calibrated Automated Thrombogram-Based Assay. Clinical Chemistry, 2012, 58, 1252-1259.	3.2	100
28	Data management in Thrombin Generation. Thrombosis Research, 2013, 131, 3-11.	1.7	99
29	Reaction Sequence of Blood Coagulation. Nature, 1967, 215, 1201-1202.	27.8	98
30	The Relative Importance of the Factors II, VII, IX and X for the Prothrombinase Activity in Plasma of Orally Anticoagulated Patients. Thrombosis and Haemostasis, 1989, 62, 788-791.	3.4	98
31	Quantitation of infarct size in man by means of plasma enzyme levels.. Heart, 1975, 37, 795-803.	2.9	90
32	Interaction of bovine blood clotting factor Va and its subunits with phospholipid vesicles. Biochemistry, 1983, 22, 2427-2432.	2.5	86
33	The Ca2+-Mobilizing Potency of alpha-Thrombin and Thrombin-Receptor-Activating Peptide on Human Platelets. Concentration and Time Effects of Thrombin-Induced Ca2+ Signaling. FEBS Journal, 1997, 249, 547-555.	0.2	85
34	Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. Journal of Thrombosis and Haemostasis, 2004, 2, 1395-1401.	3.8	85
35	The Effect of Trace Amounts of Tissue Factor on Thrombin Generation in Platelet Rich Plasma, its Inhibition by Heparin. Thrombosis and Haemostasis, 1989, 61, 025-029.	3.4	85
36	Activation of a pro-enzyme by a stoichiometric reaction with another protein. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1975, 379, 180-188.	1.7	84

#	Article	IF	Citations
37	Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2017, 15, 1704-1707.	3.8	80
38	Formation of Prothrombin Converting Activity. Nature, 1967, 215, 248-251.	27.8	78
39	Activation of human prothrombin by stoichiometric levels of staphylocoagulase.. Journal of Biological Chemistry, 1983, 258, 3637-3644.	3.4	77
40	Purification and characterization of a novel protein from bovine aorta that inhibits coagulation. Inhibition of the phospholipid-dependent factor-Xa -catalyzed prothrombin activation, through a high-affinity binding of the anticoagulant to the phospholipids. FEBS Journal, 1988, 173, 171-178.	0.2	73
41	The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. FEBS Journal, 1992, 208, 171-178.	0.2	67
42	Phenotyping the haemostatic system by thrombographyâ€"potential for the estimation of thrombotic risk. Thrombosis Research, 2004, 114, 539-545.	1.7	65
43	Activation of human prothrombin by stoichiometric levels of staphylocoagulase. Journal of Biological Chemistry, 1983, 258, 3637-44.	3.4	64
44	Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thrombosis and Haemostasis, 1993, 70, 617-24.	3.4	63
45	Thrombin generation and inactivation in the presence of antithrombin III and heparin. Biochemistry, 1986, 25, 5962-5969.	2.5	59
46	Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. Journal of Thrombosis and Haemostasis, 2006, 4, 83-89.	3.8	59
47	ELLIPSOMETRIC STUDY OF PROTEIN FILM ON CHROMIUM. Annals of the New York Academy of Sciences, 1977, 283, 77-85.	3.8	57
48	A century of heparin: past, present and future. Journal of Thrombosis and Haemostasis, 2016, 14, 2329-2338.	3.8	56
49	The balance of proâ€•and anticoagulant processes underlying thrombin generation. Journal of Thrombosis and Haemostasis, 2015, 13, 437-447.	3.8	55
50	Human Factor Va1and Factor Va2:Â Properties in the Procoagulant and Anticoagulant Pathwaysâ€. Biochemistry, 1997, 36, 3331-3335.	2.5	54
51	The adsorption of prothrombin to phospholipid monolayers quantitated by ellipsometry.. Journal of Biological Chemistry, 1984, 259, 13993-13998.	3.4	53
52	The determination of prothrombin using synthetic chromogenic substrates; choice of a suitable activator. Thrombosis Research, 1978, 13, 219-232.	1.7	52
53	Partial purification of bovine liver vitamin K-dependent carboxylase by immunospecific adsorption onto antifactor X. FEBS Letters, 1981, 123, 215-218.	2.8	52
54	New approaches for measuring coagulation. Haemophilia, 2006, 12, 76-81.	2.1	52

#	Article	IF	Citations
55	Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thrombosis and Haemostasis, 1995, 74, 134-8.	3.4	52
56	A convenient synthesis of amino acid p-nitroanilides; synthons in the synthesis of protease substrates. Tetrahedron, 1995, 51, 11235-11250.	1.9	51
57	The limits of simulation of the clotting system. Journal of Thrombosis and Haemostasis, 2006, 4, 1331-1338.	3.8	51
58	Characterization of two forms of human factor Va with different cofactor activities. Journal of Biological Chemistry, 1993, 268, 21130-6.	3.4	51
59	The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif-the C-domain. Journal of Thrombosis and Haemostasis, 2003, 1, 907-914.	3.8	49
60	The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thrombosis and Haemostasis, 2000, 83, 589-91.	3.4	48
61	Factor Xlâ€“Dependent Reciprocal Thrombin Generation Consolidates Blood Coagulation when Tissue Factor Is Not Available. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1138-1142.	2.4	47
62	Demonstration of three anomalous plasma proteins induced by a vitamin K antagonist. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1973, 317, 559-562.	1.7	46
63	The Action of a Synthetic Pentasaccharide on Thrombin Generation in Whole Plasma. Thrombosis and Haemostasis, 1989, 61, 397-401.	3.4	46
64	Meizothrombin formation during factor Xa-catalyzed prothrombin activation. Formation in a purified system and in plasma. Journal of Biological Chemistry, 1991, 266, 21864-73.	3.4	45
65	The Mode of Action of Low Molecular Weight Heparin Preparation (PK10169) and Two of its Major Components on Thrombin Generation in Plasma. Thrombosis and Haemostasis, 1989, 61, 030-034.	3.4	44
66	ORAL TREATMENT OF HÃ†MOPHILIA A BY GASTROINTESTINAL ABSORPTION OF FACTOR VIII ENTRAPPED IN LIPOSOMES. Lancet, The, 1980, 315, 70-71.	13.7	43
67	Fibrin polymerization is crucial for thrombin generation in platelet-rich plasma in a VWF-GPIb-dependent process, defective in Bernard-Soulier syndrome. Journal of Thrombosis and Haemostasis, 2004, 2, 170-176.	3.8	43
68	Kinetics of the inhibition of human factor Xa by full-length and truncated recombinant tissue factor pathway inhibitor. Biochemical Journal, 1994, 297, 131-136.	3.7	42
69	HEPARIN-LIKE INHIBITOR, NOT VITAMIN-K DEFICIENCY, IN THE NEWBORN. Lancet, The, 1977, 309, 852-853.	13.7	41
70	Is there value in kinetic modeling of thrombin generation? No (unlessâ€¦). Journal of Thrombosis and Haemostasis, 2012, 10, 1470-1477.	3.8	41
71	Separation of blood coagulation factors II , VII, IX and X by cel filtration in the presence of Dextran blue. Biochimica Et Biophysica Acta - General Subjects, 1970, 222, 692-695.	2.4	40
72	Platelet membrane involvement in blood coagulation. Nouvelle Revue FranÃ§aise D'hÃ©matologie, 1983, 9, 303-17.	0.7	40

#	Article	IF	Citations
73	Adsorption Kinetics of Protein Mixtures A Tentative Explanation of the Vroman Effect. Annals of the New York Academy of Sciences, 1987, 516, 244-252.	3.8	39
74	Annexin V inhibits the procoagulant activity of matrices of TNF-stimulated endothelium under blood flow conditions.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 824-830.	3.9	39
75	Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation. Blood, 2015, 125, 1497-1501.	1.4	39
76	Lipid Phase Transitions and Procoagulant Activity. FEBS Journal, 1979, 95, 449-457.	0.2	38
77	The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by Î±2â€macroglobulinâ€thrombin. Journal of Thrombosis and Haemostasis, 2010, 8, 1281-1289.	3.8	38
78	Functional properties of human factor Va lacking the Asp683-Arg709 domain of the heavy chain. Journal of Biological Chemistry, 1994, 269, 20662-7.	3.4	37
79	Recollections on thrombin generation. Journal of Thrombosis and Haemostasis, 2008, 6, 219-226.	3.8	36
80	Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk. Haematologica, 2007, 92, 714-715.	3.5	35
81	Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation. Haematologica, 2013, 98, 549-554.	3.5	35
82	Differences in the mechanism of blood clot formation and nanostructure in infants and children compared with adults. Thrombosis Research, 2015, 136, 1303-1309.	1.7	35
83	Inhibition of factor IXa and factor Xa by antithrombin III/heparin during factor X activation.. Journal of Biological Chemistry, 1988, 263, 15313-15318.	3.4	35
84	A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thrombosis and Haemostasis, 1986, 56, 9-17.	3.4	35
85	The adsorption of prothrombin to phospholipid monolayers quantitated by ellipsometry. Journal of Biological Chemistry, 1984, 259, 13993-8.	3.4	35
86	The technique of measuring thrombin generation with fluorogenic substrates: 3. The effects of sample dilution. Thrombosis and Haemostasis, 2009, 101, 165-170.	3.4	34
87	Membrane-mediated assembly of the prothrombinase complex. Journal of Biological Chemistry, 1991, 266, 18720-5.	3.4	34
88	Activation of human factor V by meizothrombin. Journal of Biological Chemistry, 1994, 269, 15969-72.	3.4	34
89	Analysis of thrombin generation in plasma. Computers in Biology and Medicine, 1994, 24, 277-288.	7.0	33
90	Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis. Inflammatory Bowel Diseases, 2007, 13, 753-758.	1.9	33

#	Article	IF	Citations
91	Reevaluation of some properties of fibrinogen, purified from cord blood of normal newborns. Thrombosis Research, 1983, 32, 301-310.	1.7	32
92	Autocatalytic Peptide Bond Cleavages in Prothrombin and Meizothrombinâ€. Biochemistry, 1998, 37, 1185-1191.	2.5	32
93	Phenotyping the clotting system. Thrombosis and Haemostasis, 2000, 84, 747-51.	3.4	32
94	In vitro prothrombin synthesis from a purified precursor protein III. Preparation of an acid-soluble substrate for vitamin K-dependent carboxylase by limited proteolysis of bovine descarboxyprothrombin. Biochimica Et Biophysica Acta - General Subjects, 1981, 676, 101-107.	2.4	31
95	Prothrombin conversion under flow conditions by prothrombinase assembled on adherent platelets. Blood Coagulation and Fibrinolysis, 1997, 8, 168-174.	1.0	31
96	The effect of fibrin(ogen) on thrombin generation and decay. Thrombosis and Haemostasis, 2014, 112, 486-494.	3.4	31
97	Prothrombin Contributes to the Assembly of the Factor Va-Factor Xa Complex at Phosphatidylserine-containing Phospholipid Membranes. Journal of Biological Chemistry, 1995, 270, 26883-26889.	3.4	29
98	Prothrombin Activation by Prothrombinase in a Tubular Flow Reactor. Journal of Biological Chemistry, 1995, 270, 1029-1034.	3.4	29
99	Prevention of the Influence of Fibrin and Î±2-Macroglobulin in the Continuous Measurement of the Thrombin Potential. Thrombosis Research, 1998, 89, 161-169.	1.7	29
100	Heterogeneity in microparticle formation and exposure of anionic phospholipids at the plasma membrane of single adherent platelets. Biochimica Et Biophysica Acta - Molecular Cell Research, 1999, 1451, 163-172.	4.1	29
101	The Influence of Oral Contraceptives on the Time-Integral of Thrombin Generation (Thrombin) Tj ETQq1 1 0.784314 rgBT /Overlock 10	3.4	29
102	Interaction of prothrombin with factor Va-phospholipid complexes. Biochemistry, 1984, 23, 2838-2842.	2.5	28
103	Clotting factors secreted by monocytes and macrophages: Analytical considerations. Thrombosis Research, 1985, 37, 9-19.	1.7	28
104	A comparison between vitamin K-dependent carboxylase from normal and warfarin-treated cows. Biochimica Et Biophysica Acta - General Subjects, 1982, 714, 361-365.	2.4	27
105	Evaluation of the procoagulant activity in the plasma of cancer patients using a thrombin generation assay. Thrombosis Research, 2010, 126, 531-535.	1.7	27
106	Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin. Blood Advances, 2018, 2, 1315-1324.	5.2	27
107	Antithrombin III-dependent anti-prothrombinase activity of heparin and heparin fragments. Journal of Biological Chemistry, 1989, 264, 10002-10007.	3.4	27
108	BLOOD COAGULATION FACTORS AT PHOSPHOLIPID SURFACES. Annals of the New York Academy of Sciences, 1977, 283, 104-110.	3.8	26

#	Article	IF	Citations
109	Design and synthesis of thrombin substrates with modified kinetic parameters. Thrombosis Research, 1995, 79, 491-499.	1.7	26
110	The technique of measuring thrombin generation with fluorescent substrates: 4. The H-transform, a mathematical procedure to obtain thrombin concentrations without external calibration. Thrombosis and Haemostasis, 2009, 101, 171-177.	3.4	26
111	Interindividual variation in relationships between plasma heparin concentration and the results of five heparin assays. Clinica Chimica Acta, 1982, 122, 261-270.	1.1	25
112	Thrombin generation is extremely sensitive to preheating conditions. Journal of Thrombosis and Haemostasis, 2011, 9, 233-234.	3.8	25
113	Two Types of Prothrombin in Vitamin K Deficiency. Thrombosis and Haemostasis, 1970, 23, 633-637.	3.4	25
114	Kinetics of the formation of the factor X activating enzyme of the blood coagulation system. Thrombosis Research, 1976, 8, 303-317.	1.7	24
115	Monitoring platelet dependent thrombin generation in mice. Thrombosis Research, 2010, 126, 436-441.	1.7	23
116	Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A. Journal of Thrombosis and Haemostasis, 2011, 9, 1549-1555.	3.8	23
117	Studies on the mechanism of the vitamin K-dependent carboxylation reaction. Carboxylation without the concurrent formation of vitamin K 2,3-epoxide.. Journal of Biological Chemistry, 1982, 257, 5326-5329.	3.4	23
118	The Consumption of Antithrombin III During Coagulation, Its Consequences for the Calculation of Prothrombinase Activity and the Standardisation of Heparin Activity. Thrombosis and Haemostasis, 1992, 68, 136-142.	3.4	23
119	Activation of decarboxyfactor X by a protein from Russell's Viper venom. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1978, 533, 327-341.	1.7	22
120	Procoagulant activities in venoms from central Asian snakes. Toxicon, 1991, 29, 491-502.	1.6	22
121	Prothrombinase is protected from inactivation by tissue factor pathway inhibitor: competition between prothrombin and inhibitor*. Biochemical Journal, 1997, 323, 33-37.	3.7	22
122	Identification of phospholipid as an essential part of bovine vitamin K-dependent carboxylase. Journal of Biological Chemistry, 1981, 256, 10843-6.	3.4	22
123	Purification and Characterization of Multisquamase, the Prothrombin Activator Present in Echis Multisquamatus Venom. Thrombosis Research, 1997, 88, 309-316.	1.7	21
124	During coagulation, thrombin generation shifts from chemical to diffusional control. Journal of Thrombosis and Haemostasis, 2005, 3, 2399-2400.	3.8	21
125	Low Molecular Weight Activated Protein C Inhibitors as a Potential Treatment for Hemophilic Disorders. Journal of Medicinal Chemistry, 2006, 49, 5047-5050.	6.4	21
126	Low paediatric thrombin generation is caused by an attenuation of prothrombin conversion. Thrombosis and Haemostasis, 2016, 115, 1090-1100.	3.4	21

#	Article	IF	Citations
127	Measurement of thrombin generation in whole blood--the effect of heparin and aspirin. Thrombosis and Haemostasis, 1994, 72, 78-83.	3.4	21
128	The inhibition of vitamin K-dependent carboxylase by cyanide. FEBS Letters, 1982, 137, 253-256.	2.8	20
129	Fluorogenic Peptideâ€Based Substrates for Monitoring Thrombin Activity. ChemMedChem, 2012, 7, 606-617.	3.2	20
130	The role of Î³-carboxyglutamyl residues in the positive cooperative binding of Ca2+ to blood coagulation factor X. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1978, 533, 318-326.	1.7	19
131	The placental transport of [3H] vitamin K1in rats. British Journal of Haematology, 1987, 65, 335-338.	2.5	19
132	Inhibition of Tissue Factor-Factor VIIa-catalyzed Factor X Activation by Factor Xa-Tissue Factor Pathway Inhibitor. Journal of Biological Chemistry, 1999, 274, 28225-28232.	3.4	19
133	The ionic contrast medium ioxaglate interferes with thrombin-mediated feedback activation of factor V, factor VIII and platelets. Journal of Thrombosis and Haemostasis, 2003, 1, 269-274.	3.8	19
134	The role of blood clotting factor V in the conversion of prothrombin and A decarboxy prothrombin into thrombin. Biochimica Et Biophysica Acta - General Subjects, 1978, 538, 521-533.	2.4	18
135	Kinetics of thrombin-induced release and activation of platelet factor V. FEBS Journal, 1986, 154, 213-218.	0.2	18
136	Draculin, the anticoagulant factor in vampire bat saliva, is a tight-binding, noncompetitive inhibitor of activated factor X. BBA - Proteins and Proteomics, 1999, 1434, 135-142.	2.1	18
137	Thrombin Generating Capacity and Phenotypic Association in ABO Blood Groups. PLoS ONE, 2015, 10, e0141491.	2.5	18
138	Antithrombin III-dependent anti-prothrombinase activity of heparin and heparin fragments. Journal of Biological Chemistry, 1989, 264, 10002-7.	3.4	18
139	Studies on the mechanism of the vitamin K-dependent carboxylation reaction. Carboxylation without the concurrent formation of vitamin K 2,3-epoxide. Journal of Biological Chemistry, 1982, 257, 5326-9.	3.4	18
140	In vitro prothrombin synthesis from a purified precursor protein I. Development of a bovine liver cell-free system. Biochimica Et Biophysica Acta - General Subjects, 1976, 444, 926-930.	2.4	17
141	The action of echis carinatus venom on the blood coagulation system. Demonstration of an activator of factor X. Thrombosis Research, 1984, 35, 1-9.	1.7	17
142	Purification and properties of staphylocoagulase. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1975, 379, 164-171.	1.7	16
143	Heparin-like inhibitor of blood coagulation in normal newborn. Nature, 1977, 267, 616-617.	27.8	16
144	Free factor Xa is on the main pathway of thrombin generation in clotting plasma. Biochimica Et Biophysica Acta - General Subjects, 1989, 992, 409-411.	2.4	16

#	Article	IF	Citations
145	Molecular Biology and Pathophysiology of APC Resistance: Current Insights and Clinical Implications. Seminars in Thrombosis and Hemostasis, 1998, 24, 329-335.	2.7	16
146	Linear diffusion of thrombin and factor Xa along the heparin molecule explains the effects of extended heparin chain lengths. Thrombosis Research, 2008, 122, 237-245.	1.7	16
147	The use of phosphorus oxychloride in the synthesis of amino acid pâ€nitroanilides. Recueil Des Travaux Chimiques Des Pays-Bas, 1991, 110, 347-348.	0.0	16
148	A Chromogenic Test to Determine the Procoagulant Phospholipids in Platelet-rich Plasma and Whole Blood. Thrombosis and Haemostasis, 1994, 72, 582-587.	3.4	16
149	Purification and properties of the phenprocoumon-induced decarboxyfactor X from bovine plasma. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1978, 533, 302-317.	1.7	15
150	Functional properties of factor Va subunits after proteolytic alterations by activated protein C. Biochimica Et Biophysica Acta - General Subjects, 1984, 799, 38-44.	2.4	15
151	The activity state of factor VII in plasma: two pathways for the cold promoted activation of factor VII. British Journal of Haematology, 1986, 62, 367-377.	2.5	15
152	Simulation Model for Thrombin Generation in Plasma. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1991, 21, 197-207.	0.3	15
153	Monitoring of unbound protein in vesicle suspensions with off-null ellipsometry. Biochimica Et Biophysica Acta - Biomembranes, 1993, 1147, 125-131.	2.6	15
154	A new regulatory function of activated factor V: inhibition of the activation by tissue factor/factor VII(a) of factor X. Journal of Thrombosis and Haemostasis, 2013, 11, 503-511.	3.8	15
155	The Activity of Heparin in the Presence and Absence of Ca2+ Ions; why the Anti-Xa Activity of LMW Heparins Is about two Times Overestimated. Thrombosis and Haemostasis, 1993, 70, 717-718.	3.4	15
156	Standard and Method Independent Units for Heparin Anticoagulant Activities. Thrombosis and Haemostasis, 1993, 70, 724-728.	3.4	15
157	The Adsorption of Coagulation Factors onto Phospholipids. Thrombosis and Haemostasis, 1970, 24, 214-223.	3.4	15
158	Recollections on thrombin generation. Journal of Thrombosis and Haemostasis, 2008, 6, 219-226.	3.8	15
159	Artificial Reagents for Factor VII and Factor X, a Computer Programme for Obtaining Reference Tables for One-Stage Determinations in the Extrinsic System. Thrombosis and Haemostasis, 1972, 27, 205-211.	3.4	14
160	A new method for the preparation of artificial factor II reagents from normal human and bovine plasma. Thrombosis Research, 1977, 10, 495-507.	1.7	14
161	In vitro prothombin sysnthesis from a purified precursor protein. II. Partial purification of bovine carboxylase. Biochimica Et Biophysica Acta - Biomembranes, 1978, 523, 494-505.	2.6	14
162	The ex Vivo Correlate of the Antithrombotic Action of Heparin. Annals of the New York Academy of Sciences, 1989, 556, 146-157.	3.8	14

#	Article	IF	Citations
163	Surface exclusion and molecular mobility may explain Vroman effects in protein adsorption. Journal of Biomaterials Science, Polymer Edition, 1991, 2, 217-226.	3.5	14
164	Expression of biological activity of draculin, the anticoagulant factor from vampire bat saliva, is strictly dependent on the appropriate glycosylation of the native molecule. Biochimica Et Biophysica Acta - General Subjects, 1998, 1425, 291-299.	2.4	14
165	Pharmacokinetic and Pharmacodynamic Characterization of a Medium-Molecular-Weight Heparin in Comparison with UFH and LMWH. Seminars in Thrombosis and Hemostasis, 2002, 28, 369-378.	2.7	14
166	Ratios of anti-factor Xa to antithrombin activities of heparins as determined in recalcified human plasma. British Journal of Haematology, 1992, 81, 255-262.	2.5	13
167	von Willebrand factor stimulates thrombin-induced exposure of procoagulant phospholipids on the surface of fibrin-adherent platelets. Journal of Thrombosis and Haemostasis, 2003, 1, 559-565.	3.8	13
168	The application of thrombin generation in real life clinical situations. Thrombosis Research, 2015, 136, 3-4.	1.7	13
169	A reduction of prothrombin conversion by cardiac surgery with cardiopulmonary bypass shifts the haemostatic balance towards bleeding. Thrombosis and Haemostasis, 2016, 116, 442-451.	3.4	13
170	The effect of Î³-carboxyglutamate residues on the enzymatic properties of the activated blood clotting factor X. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1978, 533, 342-354.	1.7	12
171	Laboratory monitoring of low-molecular-weight heparin therapy-part II. Journal of Thrombosis and Haemostasis, 2005, 3, 571-573.	3.8	12
172	Age-dependency of thrombin generation. Thrombosis and Haemostasis, 2006, 95, 756-757.	3.4	12
173	Sex hormone-binding globulin and thrombin generation in women using hormonal contraception. Biomarkers, 2017, 22, 81-85.	1.9	12
174	Autoactivation of human blood coagulation factor XII on dextran derivatives of different molecular weight. Thrombosis Research, 1992, 67, 665-676.	1.7	11
175	Conjectures and Refutations on the Mode of Action of Heparins. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1999, 29, 170-178.	0.3	11
176	Calibrated automated thrombinography (CAT). Thrombosis Research, 2005, 115, 255.	1.7	11
177	Caution in the interpretation of continuous thrombin generation assays: a rebuttal. Journal of Thrombosis and Haemostasis, 2007, 5, 1085-1087.	3.8	11
178	Comparison between the effect of pentosan polysulphate heparin and antithrombin III injections in antithrombin III deficient patients. Thrombosis Research, 1985, 37, 295-307.	1.7	10
179	Isolation and partial characterization of a vitamin K-dependent carboxylase from bovine aortae. Biochemical Journal, 1987, 245, 251-255.	3.7	10
180	VITAMIN-K DEFICIENCY IN THE NEWBORN. Lancet, The, 1977, 310, 708-709.	13.7	9

#	Article	IF	Citations
181	Clot-Promoting Effect of Platelet-Vessel Wall Interaction: Influence of Dietary Fats and Relation to Arterial Thrombus Formation in Rats. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1979, 8, 211-226.	0.3	9
182	Vitamin K-dependent carboxylase: the carboxylation of exogenous substrates in different systems. BBA - Proteins and Proteomics, 1985, 831, 94-98.	2.1	9
183	The Mechanism of Action of Oral Anticoagulants and Its Consequences for the Practice of Oral Anticoagulation. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1985, 15, 263-270.	0.3	9
184	Regulation of Platelet Factor Va-dependent Thrombin Generation by Activated Protein C at the Surface of Collagen-adherent Platelets. Journal of Biological Chemistry, 2001, 276, 7164-7168.	3.4	9
185	Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin. Journal of Thrombosis and Thrombolysis, 2007, 24, 175-182.	2.1	9
186	The influence of cadmium ions on the adsorption of prothrombin onto Al(OH)3 as a means to purify prothrombin. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1975, 379, 172-179.	1.7	8
187	Stimulation of the vitamin K-dependent carboxylase from bovine liver. Biochemical Journal, 1983, 209, 719-724.	3.7	8
188	Effect of heparin and low molecular weight heparins on thrombin-induced blood platelet activation in the absence of antithrombin III. Thrombosis Research, 1985, 38, 447-458.	1.7	8
189	Development of a Sensitive and Rapid Chromogenic Factor IX Assay for Clinical Use. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1990, 20, 276-288.	0.3	8
190	Simultaneous measurement of thrombin generation and fibrin formation in whole blood under flow conditions. Thrombosis and Haemostasis, 2016, 116, 134-145.	3.4	8
191	Continuous flow and the prothrombinase-catalyzed activation of prothrombin. Thrombosis and Haemostasis, 1990, 64, 542-7.	3.4	8
192	Artificial reagents for factor VII and factor X, a computer programme for obtaining reference tables for one-stage determinations in the extrinsic system. Thrombosis Et Diathesis Haemorrhagica, 1972, 27, 205-11.	0.2	8
193	Contribution of the Platelet Factor V Content to Platelet Factor 3 Activity. British Journal of Haematology, 1980, 45, 121-131.	2.5	7
194	Temperature dependent transitions in several phospholipids measured by ellipsometry. Surface Science, 1980, 96, 555-563.	1.9	7
195	On the Clot-Promoting Activity of Human Platelets in a One-Stage Prothrombinase Assay. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1982, 12, 268-274.	0.3	7
196	On the procoagulant activity of platelets stimulated by collagen and thrombin. Thrombosis Research, 1984, 33, 553-554.	1.7	7
197	Measurement of Macrophage Cellular Procoagulant Activity. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1985, 15, 108-113.	0.3	7
198	A Standard for Low Molecular Weight Heparin?. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1989, 19, 1-4.	0.3	7

#	Article	IF	Citations
199	Mode of Action of Unfractionated and Low Molecular Weight Heparins on the Generation of Thrombin in Plasma. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1990, 20, 81-92.	0.3	7
200	Development of a Rapid and Sensitive Chromogenic Heparin Assay for Clinical Use. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1993, 23, 26-37.	0.3	7
201	The contribution of ?2-macroglobulin thrombin to the endogenous thrombin potential. British Journal of Haematology, 2007, 139, 070916051811005-???.	2.5	7
202	Synthesis of peptide pâ€nitroanilides mimicking fibrinogenâ€and hirudinâ€binding to thrombin Design of slow reacting thrombin substrates. International Journal of Peptide and Protein Research, 1996, 48, 182-193.	0.1	7
203	The Mode of Action of Heparins In Vitro and In Vivo. Advances in Experimental Medicine and Biology, 1992, 313, 221-230.	1.6	7
204	Kinetic Aspects of the Interaction of Blood Clotting Enzymes. Thrombosis and Haemostasis, 1977, 37, 081-085.	3.4	7
205	The Evaluation of the Two-Stage Prothrombin Assay. Thrombosis and Haemostasis, 1971, 25, 545-554.	3.4	7
206	Kinetic Aspects of the Interaction of Blood Clotting Enzymes. Thrombosis and Haemostasis, 1965, 13, 155-175.	3.4	7
207	Reconstitution and lipid requirements of porcine tissue thromboplastin. Lipids and Lipid Metabolism, 1977, 488, 161-171.	2.6	6
208	Importance of Factor-IX-Dependent Prothrombinase Formation â€“ The Josso Pathway â€“ in Clotting Plasma. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1989, 19, 301-308.	0.3	6
209	Feedback Mechanisms in Coagulation. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1991, 21, 189-196.	0.3	6
210	Inhibition of Prothrombinase at Macroscopic Lipid Membranes: Competition between Antithrombin and Prothrombin. Biochemistry, 1995, 34, 13699-13704.	2.5	6
211	Monitoring new oral antithrombotics: what we should know before we can decide. Journal of Thrombosis and Haemostasis, 2010, 8, 2833-2835.	3.8	6
212	Studies on Blood Coagulation Factor V. Thrombosis and Haemostasis, 1969, 22, 417-430.	3.4	6
213	Activation of Factor IX by Factor XIa - A Spectrophotometric Assay for Factor IX in Human Plasma. Thrombosis and Haemostasis, 1982, 48, 127-132.	3.4	6
214	Heterogeneous biocatalysis in the generation of thrombin. Trends in Biochemical Sciences, 1982, 7, 378-381.	7.5	5
215	Use of Chromogenic Peptide Substrates in the Determination of Clotting Factors II, VII, IX and X in Normal Plasma and in Plasma of Patients Treated with Oral Anticoagulants. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1982, 12, 241-255.	0.3	5
216	Half-Life Time and Control Frequency of Vitamin K-Dependent Coagulation Factors. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1983, 13, 201-208.	0.3	5

#	Article	IF	Citations
217	Determination of the Levels of Unfractionated and Low-Molecular-Weight Heparins in Plasma: Their Effect on Thrombin-Mediated Feedback Reactions in vivo. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1991, 21, 258-272.	0.3	5
218	Production of thrombin as a probe for mixing of phospholipids in membranes on solid supports. Biochimica Et Biophysica Acta - Biomembranes, 1995, 1237, 43-48.	2.6	5
219	Can the Haemorrhagic Component of Heparin Be Identified? Or an Attempt at Clean Thinking on a Dirty Drug. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1996, 26, 117-126.	0.3	5
220	Studies on Blood Coagulation Factor V. Thrombosis and Haemostasis, 1972, 27, 025-032.	3.4	5
221	Computer evaluation of reference curves for the estimation of extrinsic coagulation factors. Computers in Biology and Medicine, 1978, 8, 65-70.	7.0	4
222	Inhibition of Thrombin-Catalyzed Reactions in Blood Coagulation and Platelet Activation by Heparin Fractions in the Absence of Antithrombin III. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1986, 16, 71-81.	0.3	4
223	The effect of factor Va on lipid dynamics in mixed phospholipid vesicles as detected by steady-state and time-resolved fluorescence depolarization of diphenylhexatriene. FEBS Journal, 1987, 164, 337-343.	0.2	4
224	Procoagulant effect of vitamin K antagonists?. Journal of Thrombosis and Haemostasis, 2011, 9, 2511-2512.	3.8	4
225	Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factorÂIXa: a rebuttal. Journal of Thrombosis and Haemostasis, 2013, 11, 564.	3.8	4
226	Exploring the limits of modelling thrombus formation. Physics of Life Reviews, 2018, 26-27, 100-105.	2.8	4
227	The Thrombotest Dilution Curve and Its Diagnostic Significance. , 1969, , 365-368.		4
228	The mode of action of CY216 and CY222 in plasma. Thrombosis and Haemostasis, 1992, 67, 33-41.	3.4	4
229	Mode of action of enoxaparin in plasma. Acta Chirurgica Scandinavica Supplementum, 1990, 556, 51-6.	0.1	4
230	The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thrombosis and Haemostasis, 1989, 61, 25-9.	3.4	4
231	Improvements of the method for the preparation of an artificial prothrombin reagent. Thrombosis Research, 1978, 12, 713-716.	1.7	3
232	The Inhibition of Platelet Prothrombinase Activity by Prostacyclin. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1984, 14, 320-324.	0.3	3
233	Determination of Low Molecular Weight Heparin in Clinical Laboratory. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1984, 14, 205-210.	0.3	3
234	Spectrophotometric Method for the Assay of Human Blood Coagulation Factor VIII. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1987, 17, 14-24.	0.3	3

#	Article	IF	Citations
235	Development of a Simple Chromogenic Factor VIII Assay for Clinical Use. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1989, 19, 196-204.	0.3	3
236	Will One Size of Anticoagulant Dosage Fit All?. Drug Development Research, 2013, 74, 406-412.	2.9	3
237	Comment on the use of computational models to study the effect of apixaban and rivaroxaban on thrombin generation. Thrombosis and Haemostasis, 2016, 115, 869-870.	3.4	3
238	Computational modelling of clot development in patientâ€specific cerebral aneurysm cases: comment. Journal of Thrombosis and Haemostasis, 2017, 15, 395-396.	3.8	3
239	Studies on Blood Coagulation Factor V. Thrombosis and Haemostasis, 1972, 27, 033-042.	3.4	3
240	Inhibition of blood coagulation factors by serine esterase inhibitors. FEBS Letters, 1972, 24, 265-268.	2.8	2
241	Partial Purification of the Protein Moiety of Porcine Tissue Thromboplastin. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1977, 6, 269-282.	0.3	2
242	Control of Anticoagulant Therapy with a Chromogenic Substrate. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1979, 8, 1-7.	0.3	2
243	Heparin Neutralization during Collection and Processing of Blood Inhibited by Pyridoxal 5â€²-Phosphate. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1984, 14, 253-261.	0.3	2
244	The love of the artist for his model of thrombin generation. Journal of Thrombosis and Haemostasis, 2004, 2, 400-401.	3.8	2
245	IN MEMORY OF FRANÃ‡OIS JOSSO. Scandinavian Journal of Haematology, 1984, 33, 11-19.	0.0	2
246	No Effect of Ethanol Intake on Thrombin Generation Parameters. Thrombosis Research, 2012, 129, 530-531.	1.7	2
247	The consumption of antithrombin III during coagulation, its consequences for the calculation of prothrombinase activity and the standardisation of heparin activity. Thrombosis and Haemostasis, 1992, 68, 136-42.	3.4	2
248	Inhibition of prothrombinase by antithrombin-heparin at a macroscopic surface. Thrombosis and Haemostasis, 1995, 73, 648-53.	3.4	2
249	Anticoagulants in Acute Myocardial Infarction. BMJ: British Medical Journal, 1969, 2, 445-445.	2.3	1
250	CONTROL OF LONG-TERM ANTICOAGULANT TREATMENT. Lancet, The, 1970, 295, 894.	13.7	1
251	Estimation of the rate constants in the michaelis-menten equations without restrictions as to time scale. FEBS Letters, 1972, 24, 293-295.	2.8	1
252	Paratopic interaction, a mechanism in the generation of structure bound enzymatic activity. Experientia, 1977, 33, 851-853.	1.2	1

#	Article	IF	Citations
253	The Synthesis of Prothrombin from Its Precursor Protein. Current Studies in Hematology and Blood Transfusion, 1977, 44, 54-60.	0.2	1
254	A coagulation reagent completely devoid of factor X; Relation between clotting time and concentration of factor X. Thrombosis Research, 1979, 14, 679-685.	1.7	1
255	An inhibitor of clot formation in cord plasma. Thrombosis Research, 1979, 15, 389-403.	1.7	1
256	The Role of Surfaces in the Mechanism of Blood Coagulation. , 1979, , 134-158.		1
257	Editorial Note reduction of infarct size: discrepancies between experimental work and clinical application. International Journal of Cardiology, 1983, 2, 347-348.	1.7	1
258	Automated Spectrophotometric Heparin Assays. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1984, 14, 195-204.	0.3	1
259	Automated Determination of Heparin with Chromogenic Substrates. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1984, 14, 184-194.	0.3	1
260	Role of Accessory Components in the Activation of Vitamin K-Dependent Coagulation Factors. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1986, 16, 216-226.	0.3	1
261	The prolongation of the thrombotest clotting time in newborns. Thrombosis Research, 1988, 52, 45-52.	1.7	1
262	Elements from in vitro studies that help understand the action of heparins. Thrombosis Research, 1991, 61, 1-10.	1.7	1
263	Mathematical and biological models of blood coagulation. A rebuttal. Journal of Thrombosis and Haemostasis, 2006, 4, 710-711.	3.8	1
264	Computational modelling of clot development in patientâ€specific cerebral aneurysm cases: rebuttal. Journal of Thrombosis and Haemostasis, 2017, 15, 399-399.	3.8	1
265	Measuring the conversion of a chromogenic substrate. , 1983, , 27-51.		1
266	Activation of Bovine Factor IX By Bovine Factor XIa . Active Site Titration Of Factor IXa and Development of A spectro-Photometric assay for Factor IX. Thrombosis and Haemostasis, 1981, 46, .	3.4	1
267	About the Cost of Opposing the Coumarin-Inhibitor Theory â€“ Reply. Thrombosis and Haemostasis, 1983, 49, 247-247.	3.4	1
268	Mode of action of heparin and related drugs. Seminars in Thrombosis and Hemostasis, 1991, 17 Suppl 1, 29-34.	2.7	1
269	Detection of heterozygotes for factor 8, 9, and 12 deficiency. Thrombosis Et Diathesis Haemorrhagica Supplementum, 1965, 17, 181-9.	0.0	1
270	Differential Interaction of Clotting Factors II, VII, IX and X with Sephadex and Dextran Blue. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1972, 1, 237-252.	0.3	0

#	Article	IF	Citations
271	Enzymes and Paraenzymes in the Sequential Reactions in Blood Coagulation. Biochemical Society Transactions, 1973, 1, 1189-1191.	3.4	0
272	Different Properties of Factor VIII in Von Willebrandâ€™s Disease with Respect to Recovery in Cryoprecipitate. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1974, 3, 142-148.	0.3	0
273	The influence of glycerol on the Ca flux in the isolated perfused rat heart. Basic Research in Cardiology, 1976, 71, 252-262.	5.9	0
274	A quick method for the determination of decarboxyfactor X. Thrombosis Research, 1978, 12, 1071-1078.	1.7	0
275	Thrombosis service in The Netherlands. International Journal of Cardiology, 1981, 1, 215-216.	1.7	0
276	A New Method To Determine The Binding Of Factor X To Phospholipid Bilayers. Thrombosis and Haemostasis, 1981, 46, 0263.	3.4	0
277	Inhibition of Activated Factors II, VII, IX, and X by Synthetic Organic Compounds Directed against the Active-Site Seryl Residue. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1981, 10, 315-347.	0.3	0
278	THE ROLE OF HEPARIN CHARGE DENSITY IN THE ANTITHROMBIN III-DEPENDENT AND ANTITHROMBIN III-INDEPENDENT INACTIVATION OF THROMBIN. Thrombosis and Haemostasis, 1987, 58, 1558.	3.4	0
279	THE PROLONGATION OF THE THROMBOTEST CLOTTING TIME IN NEWBORNS. Thrombosis and Haemostasis, 1987, 58, 1470.	3.4	0
280	THE MODE OF ACTION OF PENTOSAN POLYSULPHATE IN PLASMA. Thrombosis and Haemostasis, 1987, 58, 0450.	3.4	0
281	A NEW CASE OF A CONGENITAL COMBINED HYPO-DYSFIBRINOGENEMIA?. , 1987, 58, 0536.		0
282	GLA-CONTAINING PROTEINS FROM CALCIFIED HUMAN ATHEROSCLEROTIC PLAQUES. , 1987, 58, 0948.		0
283	INHIBITION OF FACTOR Xa AND THROMBIN BY ANTITHROMBIN III AND HEPARIN DURING HUMAN PROTHROMBIN ACTIVATION. Thrombosis and Haemostasis, 1987, 58, 0967.	3.4	0
284	DEVELOPMENT OF A SIMPLE FACTOR VIII-ASSAY FOR CLINICAL USE. Thrombosis and Haemostasis, 1987, 58, 1235.	3.4	0
285	An investigation of the coagulological potential of the venoms of some Central Asian snakes. Chemistry of Natural Compounds, 1993, 29, 384-390.	0.8	0
286	Enzyme Kinetic Evaluation of Coagulation Systems. , 1969, , 104-110.		0
287	Discrepancies between the One- and Two-Stage Prothrombin Estimations in Purified Prothrombin Preparations. , 1975, , 89-92.		0
288	CLOTTING FACTOR DEPENDENCY OF PROTHROMBINASE ACTIVITY IN DICOUMAROL PLASMA. THE IMPORTANCE OF A FACTOR IX DEPENDENT PATHWAY IN EXTRINSIC COAGULATION. , 1987, 58, .		0

#	Article	IF	Citations
289	A Method for Measuring Activated Factor VIII in Plasma. Thrombosis and Haemostasis, 1991, 66, 430-434.	3.4	0
290	The Mechanisms of Thrombin Formation. , 1991, , 3-16.		0
291	Peptide p-nitroanilides: Chromogenic substrates for the determination of the thrombin generation curve. , 1995, , 901-902.		0
292	Determinations that can be carried out with chromogenic substrates. , 1983, , 95-123.		0
293	Substrates. , 1983, , 53-93.		0
294	A rational approach to heparins. , 1992, 34, 5-9.		0